Skip to main content

1 Result(s)

within Hiromi Muta Remove this filter Biomedicine Remove this filter

and

  1. No Access

    Article

    CD30: from basic research to cancer therapy

    The FDA recently approved an agonistic anti-CD30 drug conjugate, Brentuximab vedotin, for the treatment for CD30-positive lymphomas. The potent clinical activity of Brentuximab vedotin in Hodgkin’s lymphoma a...

    Hiromi Muta, Eckhard R. Podack in Immunologic Research (2013)